Drugs / β-globin restored autologous hematopoietic stem cells
β-globin restored autologous hematopoietic stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05745532 | Dec 2020 → May 2025 overdue | beta-thalassemia major | Shenzhen Hemogen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | β-globin restored autologous hematopoietic stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05745532 ↗ |
| Action | Restore | “to restore β-globin expression” NCT05745532 ↗ |
| Modality | Cell therapy | “autologous hematopoietic stem cells” NCT05745532 ↗ |